2. Academic Validation
  3. A pan-coronavirus peptide inhibitor prevents SARS-CoV-2 infection in mice by intranasal delivery

A pan-coronavirus peptide inhibitor prevents SARS-CoV-2 infection in mice by intranasal delivery

  • Sci China Life Sci. 2023 Oct;66(10):2201-2213. doi: 10.1007/s11427-023-2410-5.
Lili Wu # 1,  Anqi Zheng # 1 2,  Yangming Tang # 3,  Yan Chai # 1,  Jiantao Chen 3,  Lin Cheng 4,  Yu Hu 1 5,  Jing Qu 6,  Wenwen Lei 7,  William Jun Liu 7,  Guizhen Wu 7,  Shaogui Zeng 3,  Hang Yang 8 9 10,  Qihui Wang 11 12,  George Fu Gao 13 14 15
Affiliations

Affiliations

  • 1 CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, 100101, China.
  • 2 University of the Chinese Academy of Sciences, Beijing, 100049, China.
  • 3 Hybio Pharmaceutical Co., Ltd., Shenzhen, 518109, China.
  • 4 Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, Shenzhen, 518112, China.
  • 5 School of Life Sciences, University of Science and Technology of China, Hefei, 230026, China.
  • 6 Shenzhen Center for Disease Control and Prevention, Shenzhen, 518055, China.
  • 7 NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China.
  • 8 University of the Chinese Academy of Sciences, Beijing, 100049, China. yangh@wh.iov.cn.
  • 9 CAS Key Laboratory of Special Pathogens and Biosafety, Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, China. yangh@wh.iov.cn.
  • 10 Hubei Jiangxia Laboratory, Wuhan, 430299, China. yangh@wh.iov.cn.
  • 11 CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, 100101, China. wangqihui@im.ac.cn.
  • 12 University of the Chinese Academy of Sciences, Beijing, 100049, China. wangqihui@im.ac.cn.
  • 13 CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, 100101, China. gaof@im.ac.cn.
  • 14 University of the Chinese Academy of Sciences, Beijing, 100049, China. gaof@im.ac.cn.
  • 15 Chinese Center for Disease Control and Prevention (China CDC), Beijing, 102206, China. gaof@im.ac.cn.
  • # Contributed equally.
PMID: 37574525 DOI: 10.1007/s11427-023-2410-5
Abstract

Coronaviruses (CoVs) have brought serious threats to humans, particularly severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2), which continually evolves into multiple variants. These variants, especially Omicron, reportedly escape therapeutic Antibodies and vaccines, indicating an urgent need for new antivirals with pan-SARS-CoV-2 inhibitory activity. We previously reported that a peptide fusion inhibitor, P3, targeting heptad repeated-1 (HR1) of SARS-CoV-2 spike (S) protein, could inhibit viral infections. Here, we further designed multiple derivatives of the P3 based on structural analysis and found that one derivative, the P315V3, showed the most efficient Antiviral activity against SARS-CoV-2 variants and several Other sarbecoviruses, as well as Other human-CoVs (HCoVs). P315V3 also exhibited effective prophylactic efficacy against the SARS-CoV-2 Delta and Omicron variants in mice via intranasal administration. These results suggest that P315V3, which is in Phase II clinical trial, is promising for further development as a nasal pan-SARS-CoV-2 or pan-CoVs inhibitor to prevent or treat CoV diseases.

Keywords

SARS-CoV-2; intranasal delivery; pan-coronavirus; peptide fusion inhibitor; viral infection.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z